March 28th 2023
Durvalumab plus tremelimumab and hypofractionated radiotherapy yields observable clinical benefits in patients with gynecologic cancers, according to an expert from The University of Texas MD Anderson Cancer Center.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
The 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
Community Practice Connections®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?
Medical Crossfire®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?
Medical Crossfire®: How Are We Integrating Immune Checkpoint Inhibitors and Targeted Therapies to Personalize Therapy in Endometrial Cancer?
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Burst CME™: What You Need to Know About the Evolving Role of TIL Therapy in Cancer Treatment
Endometrioid Ovarian Cancer Presents Earlier, Offers Better Survival Than Serous CarcinomaJanuary 20th 2017
Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.
VCAM-1 Expression Linked to Poor Survival in Epithelial Ovarian CancerNovember 24th 2016
Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.
Novel WEE1 Inhibitor Increases Chemotherapy Efficacy in Ovarian CancerNovember 3rd 2016
Adding the WEE1 inhibitor AZD1775 to carboplatin offered enhanced response rates in women with TP53-mutated ovarian cancer that was refractory or resistant to first-line platinum-based therapy in a phase II study.
HPV Vaccination Schedule Change for Children, AdolescentsNovember 2nd 2016
The Centers for Disease Control and Prevention (CDC) has changed recommendations on the human papillomavirus (HPV) vaccine schedule in 11- and 12-year-old children from 3 doses to 2 doses in at least 6-month intervals.
Seribantumab Fails to Improve PFS in Ovarian Cancer; Some Patients May BenefitOctober 27th 2016
Adding seribantumab to paclitaxel failed to improved progression-free survival in unselected patients with platinum-resistant or -refractory ovarian cancer. Expression of heregulin and HER2, however, could identify a subset of patients that derive benefit from the therapy.
Rucaparib Demonstrates Strong Activity in BRCA-Mutated Advanced Ovarian CancerOctober 18th 2016
The oral PARP inhibitor rucaparib showed strong activity and an acceptable safety profile in women with high-grade, BRCA-mutated ovarian carcinoma who had previously received at least two lines of chemotherapy.
For 5 decades, Maine, Vermont, and New Hampshire have reported a 20% higher rate of bladder cancer than the United States overall. A recent extensive population-based, case-control study sought to evaluate suspected risk factors for these findings -- namely, the presence of arsenic in drinking water from private wells.
Does Surveillance With CA-125 in Ovarian Cancer Benefit Patients?September 22nd 2016
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that found that surveillance with CA-125 in ovarian cancer patients led to more use of chemotherapy, decreased quality of life, and no improvement in survival.
ACR Appropriateness Criteria® Adjuvant Management of Early-Stage Endometrial Cancer
After a review of the published literature, the panel voted on three variants to establish best practices for the utilization of imaging, radiotherapy, and chemotherapy after primary surgery for early-stage endometrial cancer.
Ovarian Cancer Mortality Declining in United States, EuropeSeptember 9th 2016
Ovarian cancer mortality rates declined significantly in several parts of the world from 2002 to 2012, according to a new study. Among the main reasons for the decline is the use of oral contraceptives, particular in the United States and European Union.
HIV Infection Decreases Survival in Women With Invasive Cervical CancerAugust 30th 2016
HIV infection significantly decreases survival among women with invasive cervical cancer, according to a study conducted in Botswana. This was the case even though most women with HIV received antiretroviral therapy.
Power Morcellation Use for Hysterectomy Decreased Since FDA WarningAugust 28th 2016
The use of electric power morcellation for hysterectomy has declined since the FDA warned that the procedure, which fragments the uterus into smaller pieces, may result in the spread of undetected malignancies.
ASCO Issues Guideline on Neoadjuvant Chemotherapy for Advanced Ovarian CancerAugust 8th 2016
In a new practice guideline, the American Society of Clinical Oncology offered recommendations on the use of neoadjuvant chemotherapy and interval cytoreduction for women with stage IIIC or IV epithelial ovarian cancer.